PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement.

Ghassan K.  Abou-Alfa

Consulting or Advisory Role - Adicet Bio; Alnylam; AstraZeneca; Autem Medical; BeiGene; Berry Genomics; Celgene (I); Center for Emerging & Neglected Diseases (CEND) (I); CytomX Therapeutics (I); Eisai; Exelixis; Flatiron Health; Genoscience Pharma; Helio Health; Incyte; Ipsen; Lilly (I); Merck Serono; Nerviano Medical Sciences; QED Therapeutics; Rafael Pharmaceuticals (I); RedHill Biopharma; Roche/Genentech; SERVIER; Silenseed (I); SOBI (I); Vector Health; Yiviva; Yiviva

Research Funding - Agios (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Bayer (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Flatiron Health (Inst); Genentech/Roche (Inst); Genoscience Pharma (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Silenseed (Inst); Yiviva (Inst)

Travel, Accommodations, Expenses - Polaris

Ivan  Borbath

Honoraria - Bayer (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst)

Consulting or Advisory Role - Lilly (Inst)

Research Funding - SERVIER (Inst)

Travel, Accommodations, Expenses - Ipsen (Inst)

Lipika  Goyal

Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; Exelixis; Genentech; H3 Biomedicine; Incyte; Klus Pharma; QED Therapeutics; Sirtex Medical; Taiho Pharmaceutical

(OPTIONAL) Uncompensated Relationships - Agios; Debiopharm Group; Merck; Taiho Pharmaceutical

Angela  Lamarca

Consulting or Advisory Role - Albireo Pharma; AstraZeneca/MedImmune; Boston Scientific; Eisai; Ipsen; Nutricia; Nutricia (I); QED Therapeutics; Roche; SERVIER

Speakers' Bureau - Advanced Accelerator Applications; AstraZeneca/MedImmune; Eisai; Incyte; Ipsen; Ipsen (I); Merck; Novartis (I); Pfizer; Pfizer (I); QED Therapeutics; SERVIER

Research Funding - Ipsen; Ipsen (I); Roche

Travel, Accommodations, Expenses - Abbott Nutrition; Advanced Accelerator Applications; Bayer; Celgene; Delcath Systems; Ipsen; Ipsen (I); Mylan; NanoString Technologies (I); Novartis; Pfizer; Sirtex Medical

Teresa  Macarulla

Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Ellipses Pharma; Genzyme; Hirslanden/GITZ; Imedex; Incyte; Ipsen; Janssen; Lilly; Medscape; Menarini; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Paraxel; Polaris Consulting; PPD; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; Scilink Comunicación Científica SC; SERVIER; Surface Oncology; Swedish Orphan Biovitrum; Zymeworks

Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER

Do-Youn  Oh

Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Zymeworks

Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER

Sameek  Roychowdhury

Stock and Other Ownership Interests  - Johnson & Johnson (I)

Honoraria - Illumina; Integrated DNA Technologies

Consulting or Advisory Role - AbbVie; Incyte; Merck; QED Therapeutics

Research Funding - Ignyta; Incyte; QED Therapeutics; Takeda

Saeed  Sadeghi

Honoraria - Eisai; Lilly; QED Therapeutics

Speakers' Bureau - AstraZeneca/MedImmune; Eisai; Eisai; Eisai; Eisai; GlaxoSmithKline; Lilly; QED Therapeutics; QED Therapeutics

Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); QED Therapeutics (Inst); Sanofi/Aventis (Inst); Zymeworks (Inst)

Rachna T.  Shroff

Consulting or Advisory Role - AstraZeneca; Basilea; Boehringer Ingelheim; Exelixis; Genentech; Incyte; Merck; QED Therapeutics; SERVIER; Taiho Pharmaceutical

Research Funding - Bayer; Bristol-Myers Squibb; Exelixis; Faeth Therapeutics; Immunovaccine; Loxo/Lilly; Merck; Novocure; Nucana; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen; Taiho Pharmaceutical

Ai  Li

Employment - QED Therapeutics

Stock and Other Ownership Interests  - QED Therapeutics

Jose  Soto

No Relationships to Disclose

Francesca  Avogadri

Employment - QED Therapeutics

Stock and Other Ownership Interests  - QED Therapeutics

Carl L.  Dambkowski

Employment - QED Therapeutics

Stock and Other Ownership Interests  - QED Therapeutics

Milind M.  Javle

Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences

Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics

Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen